Vinge has advised Cellink AB, listed on Nasdaq Stockholm, in connection with the acquisition of all shares in Scienion Ag. Scienion is a life science company which focuses on precision dimensioning technology.
Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.
Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with its acquisition of a controlling interest of 62.7% of the French company Genkyotex SA, a leader in NOX inhibition therapies and listed on Euronext Paris and Euronext Brussels.
The board of directors of Samhällsbyggnadsbolaget i Norden has, on the basis of an authorization granted by the annual general meeting, resolved on a directed issue of class D shares and a directed issue of subordinated convertibles mandatorily convertible into class B shares, whereby the company raises proceeds of SEK 3.4 billion before issue costs.
Vinge has advised Scandic Hotels Group AB (publ) on a fully underwritten rights issue, which will provide Scandic with issue proceeds amounting up to approximately SEK 1,765 million before deduction of transaction costs, and on the agreement of new credit facilities amounting to SEK 1,400 million.
The board of directors of Hansa Biopharma has, on the basis of an authorisation granted from the annual general meeting, resolved on a directed new issue of shares, whereby Hansa Biopharma will raise proceeds of SEK 1.1 billion, before issue costs.
Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 185 million in issue proceeds.
